눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
NFPA 704
0
2
0
AST2818 mesylate C화학적 특성, 용도, 생산
개요
Furmonertinib (formerly known as alflutinib) is another me-too third-generation EGFR TKI that has a pyridyl ring replacing the phenyl ring of osimertinib and a trifluoroethyl group replacing the methyl group (Fig. 4). This TKI, which was discovered and developed by Shanghai Allist Pharma, was approved in November 2019 by the NMPA of China for the second-line treatment of NSCLC with EGFR sensitive mutation and EGFR T790M drug-resistant mutation, and more recently as a first-line treatment for classical EGFR mutant NSCLC. In June 2022, furmonertinib was granted the Fast Track designation by the FDA in patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations, including exon 20 insertion mutations.